Human papillomavirus type 16 E6 and E7 oncoproteins interact with the nuclear p53-binding protein 1 in an in vitro reconstructed 3D epithelium: new insights for the virus-induced DNA damage response by Squarzanti, Diletta Francesca et al.








Human papillomavirus type 16 E6 and E7 oncoproteins interact with the
nuclear p53-binding protein 1 in an in vitro reconstructed 3D epithelium:
new insights for the virus-induced DNA damage response
Squarzanti, Diletta Francesca; Sorrentino, Rita; Landini, Manuela Miriam; Chiesa, Andrea; Pinato,
Sabrina; Rocchio, Francesca; Mattii, Martina; Penengo, Lorenza; Azzimonti, Barbara
Abstract: BACKGROUND Despite vaccination and screening measures, anogenital cancer, mainly pro-
moted by HPV16 oncoproteins, still represents the fourth tumor and the second cause of death among
women. Cell replication fidelity is the result of the host DNA damage response (DDR). Unlike many DNA
viruses that promote their life cycle through the DDR inactivation, HR-HPVs encourage cells proliferation
despite the DDR turned on. Why and how it occurs has been only partially elucidated. During HPV16
infection, E6 links and degrades p53 via the binding to the E6AP LXXLL sequence; unfortunately, E6
direct role in the DDR response has not clearly identified yet. Similarly, E7 increases DDR by competing
with E2F1-pRb interaction, thus leading to the inactivation of pRb, and promotion, E2F1 mediated,
of DDR genes translation, by binding to the pRb-like proteins CBP/p300 and p107, that also harbour
LXXLL sequence, and via the interaction and activation of several DDR proteins. METHODS To gain
information regarding E6 and E7 contribution in DDR activation, we produced an in vitro 3D HPV16-
E6E7 infected epithelium, already consolidated study model for HPVs, and validated it by assessing HE
staining and BrdU, HPV16 DNA, E6E7 proteins and ￿H2A.X/53BP1 double-strand break (DSBs) sensors
expression; then we made an immuno-colocalization of E6 and E7 with cyclin E2 and B1. Since 53BP1,
like E6 and E7, also binds p53 and pRb, we supposed their possible direct binding. To explore this
hypothesis, we performed a double immunofluorescence of E6 and E7 with 53BP1, a sequence analysis of
53BP1 within its BRCT2 domain and then an in situ PLA within CaSki, E6E7HPV16 NHEKs and the
3D model. RESULTS The in vitro epithelium resembled the histology and the events typical of in vivo
infected tissues. E6E7HPV16 were both expressed in basal and differentiated strata and induced H2A.X
phosphorylation and 53BP1 increment into nuclear foci. After highlighting E6 and E7 co-expression with
53BP1 and a LKVLL sequence within the 53BP1 BRCT2 domain, we demonstrated the bindings via
the PLA technique. CONCLUSIONS Our results reinforce E6 and E7 role in cellular function control
providing potentially new insights into the activity of this tumor virus.
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Abstract
Background: Despite vaccination and screening measures, anogenital cancer, mainly promoted by HPV16
oncoproteins, still represents the fourth tumor and the second cause of death among women.
Cell replication fidelity is the result of the host DNA damage response (DDR). Unlike many DNA viruses that
promote their life cycle through the DDR inactivation, HR-HPVs encourage cells proliferation despite the DDR
turned on. Why and how it occurs has been only partially elucidated.
During HPV16 infection, E6 links and degrades p53 via the binding to the E6AP LXXLL sequence; unfortunately,
E6 direct role in the DDR response has not clearly identified yet.
Similarly, E7 increases DDR by competing with E2F1-pRb interaction, thus leading to the inactivation of pRb, and
promotion, E2F1 mediated, of DDR genes translation, by binding to the pRb-like proteins CBP/p300 and p107, that
also harbour LXXLL sequence, and via the interaction and activation of several DDR proteins.
Methods: To gain information regarding E6 and E7 contribution in DDR activation, we produced an in vitro 3D
HPV16-E6E7 infected epithelium, already consolidated study model for HPVs, and validated it by assessing H&E
staining and BrdU, HPV16 DNA, E6E7 proteins and γH2A.X/53BP1 double-strand break (DSBs) sensors expression;
then we made an immuno-colocalization of E6 and E7 with cyclin E2 and B1.
Since 53BP1, like E6 and E7, also binds p53 and pRb, we supposed their possible direct binding. To explore this
hypothesis, we performed a double immunofluorescence of E6 and E7 with 53BP1, a sequence analysis of 53BP1
within its BRCT2 domain and then an in situ PLA within CaSki, E6E7HPV16 NHEKs and the 3D model.
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Results: The in vitro epithelium resembled the histology and the events typical of in vivo infected tissues.
E6E7HPV16 were both expressed in basal and differentiated strata and induced H2A.X phosphorylation and 53BP1
increment into nuclear foci.
After highlighting E6 and E7 co-expression with 53BP1 and a LKVLL sequence within the 53BP1 BRCT2 domain, we
demonstrated the bindings via the PLA technique.
Conclusions: Our results reinforce E6 and E7 role in cellular function control providing potentially new insights into
the activity of this tumor virus.
Keywords: High-risk Human Papillomavirus, Cancer, DNA damage response, E6-associated protein, Double-strand
break, In vitro 3D epithelial model, Proximity ligation assay, World Health Organization, Genomic instability
Background
Human papillomavirus (HPV) family groups a heteroge-
neous number of viruses able to infect squamous stratified
epithelia and cause benign papillomas, warts and anogeni-
tal lesions, depending on the viral genotype, time of
persistence and possible integration into the eukaryotic
host genome. The virus also correlates with oropharyngeal
malignancies, strongly rising because of sexual behaviors
changes [1].
HPV vaccine, the first one developed in 1991, till now
represents, with its 2-, 4- and 9-valent formulations, the
best way to prevent and control both infection and geni-
tal cancer progression that are mainly mediated by high
risk HPV16 and 18 oncoproteins. Ten years of phase III
clinical trials revealed their optimal effectiveness with
success rates ranging from 90 to 100%, although to be
confirmed by a 20 years overall period of clinical evi-
dences [2, 3].
Despite this and the strict screening measures, ano-
genital cancer, mainly promoted by the over-expression
of the high risk α-HPV16 E6 and E7 oncoproteins which
destabilize the host genome over time after primary in-
fection [4–6], still represents the fourth most common
tumor and the second largest cause of death among
women in the world, with about more than 5 hundred
thousand new cases/year, as evidenced by the World
Health Organization (WHO).
Cell replication fidelity is the result of the host DDR.
Unlike many DNA viruses that promote their life cycle
through the DDR inactivation, HR-HPVs encourage cells
proliferation despite the DDR turned on. Why and how
it occurs has only partially elucidated.
Although a lot of research has been published in the
area [7–9], further insights are needed to deepen the
replication and host genome destabilizing properties of
the virus, from the early phases of the tumorigenesis
process, in order to discover new target therapies for un-
vaccinated HPV infected patients and for those in whom
vaccination is not the right approach.
Well established reports demonstrate that HR-HPVs can
efficiently amplify their genome thanks to the independent,
but cooperative ability of E6 and E7 oncoproteins to
manipulate the DDR and repair machinery of the tar-
geted host’s epithelial cells [10–14], activated just after
the oncogene-induced replicative stress, leading to gen-
omic instability (GIN) and cancer progression [15–18].
It is well known that HR-HPV16 E6 oncoprotein is
highly expressed during the early phases of infection
and responsible for p53 degradation, via the prote-
asome machinery, through the binding with E6AP, a
HECT domain ubiquitin ligase [19]. Both E6 and E6AP
alone are unable to bind p53, suggesting that their
interaction is crucial for p53 degradation [20–22];
indeed, structure analysis reveals that such binding
induces conformational changes in E6AP that allow the
link with p53 [23].
The E6AP binding relies on a short leucine rich ami-
noacidic sequence, called LXXLL binding motif; when
deleted and/or mutated, the formation of the E6-E6AP
complex is prevented, thus failing to target p53 for deg-
radation [21, 23–25].
Similarly, E7 increases DDR through several mecha-
nisms: by competing with E2F1-pRb interaction, thus
leading to the inactivation of pRb, and promotion, E2F1
mediated, of DDR genes translation, by binding to the
pRb-like proteins CBP/p300 and p107, that also harbour
LXXLL sequence, and via the interaction and activation
of several DDR proteins.
Because of E6 and E7 interaction with several LXXLL
binding motif containing proteins [26–30], we hypothe-
sized their binding also to one of the LXXLL motifs con-
tained into DNA damage sensors.
On these bases, we show experimental evidences to
support our theory by using an in vitro reconstructed
3D infected epithelium [31–34], made of HPV16E6E7
transduced keratinocytes and already consolidated for
HPVs study, as a surrogate of an in vivo lesion. H/E
and immunofluorescence stainings for the main viral
markers (HPV16-DNA, E6 and E7), DSBs sensors
γH2A.X and 53BP1 and cyclins (E2 and B1) were firstly
made in order to reproduce, inside the 3D model, what
in vivo happens.
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Afterwards, despite the existence of many DNA dam-
age sensor targets such as 53BP1, well-recognized DDR
mediator/adaptor, MDC1 (mediator of DNA Damage
Checkpoint 1), BRCA1 (Breast Cancer 1, early onset),
TOPBP1 (Topoisomerase II-binding protein 1) and Clas-
pin, we supposed that E6 and E7 could directly interfere
just on 53BP1 activity since they all respectively link to
p53 and pRb for the control of anti-tumorigenic cell-fate
decisions and for their rapid proteasome-mediated deg-
radation and inactivation respectively.
After highlighting E6 and E7 co-expression with
53BP1 by IF analysis, [35–41] and found the presence of
a LXXLL binding motif within the 53BP1 BRCT2 do-
main (LKVLL), we finally evidenced the complex and
direct interaction between E6 and E7 HPV16 oncopro-
teins with 53BP1 via the highly specific and sensible in
situ PLA system [42–46], well known and validated
assay able to identify and characterize interactions in na-
tive proteins in their correct tissue/cell context under
near natural/physiological conditions.
Methods
Normal and HPV16 positive neoplastic epithelia
Normal epithelia, obtained by the tumor-free margins of
informed consent patients who underwent surgical pro-
cedures, and HPV16 positive anogenital intraepithelial
neoplasia (AIN, grade III), selected by the records of the
Pathology Unit of the Azienda Ospedaliero-Universitaria
“Maggiore della Carità” of Novara, Italy, were used as
the in vivo counterpart of the 3D models.
2D cell cultures
Authenticated pooled neonatal normal human epider-
mal keratinocytes (NHEKs) were obtained from Lonza
(distributed by Euroclone, Milan, Italy) and used to
produce, by lentiviral infection, LacZ and E6E7 HPV16
keratinocytes (control normal and E6E7HPV16 NHEKs)
as previously described by Azzimonti et al. [47]. Epithe-
lial cells were grown in monolayer in EpiLife® Medium
(Invitrogen, Milan, Italy).
Certified human dermal fibroblasts (HDFs) were bought
from ATCC (distributed by LGC Standards, Sesto San
Giovanni, Milan, Italy) and maintained in DMEM supple-
mented with 10% heat inactivated fetal bovine serum
(FBS) both from Sigma Aldrich (Milan, Italy) at 37 °C in a
humidified 5% CO2 atmosphere.
CaSki cell line, reported to contain an integrated
HPV16 genome (about 600 copies per cell) [48], was also
obtained by ATCC and maintained as above described.
3D in vitro epithelial cultures establishment
3D epithelial cultures were prepared as previously de-
scribed [47, 49, 50], with some modifications. Briefly,
normal and E6E7HPV16 NHEKs (1x106cells), produced
as shown in the 2D culture paragraph, were seeded onto
type I rat tail collagen plugs embedded with HDFs and
kept submerged for four days. Cultures were then raised
at the air-liquid interface for 14 days, with culture medium
change every other day. To mark cells in S phase, eighteen
hours before harvesting they were exposed to BrdU
(5′-bromo-2′-deoxyuridine, 100μg/ml, Sigma Aldrich). In
vivo and in vitro normal and HPV16 positive specimens
were fixed in 10% buffered formalin, embedded in
paraffin, cut into 4-μm-thick sections, placed onto
Superfrost ultra plus glass slides (Menzel Glaser, distrib-
uted by BioOptica, Milan, Italy) and counterstained by
hematoxylin and eosin (H&E; Sigma Aldrich; Fig. 1A-D).
3D in vitro epithelial cultures analysis
HPV16 DNA fluorescent in situ hybridization (FISH) and
BrdU stainings
HPV16 DNA detection was performed onto the normal
and HPV16 positive 3D tissues as described by Peh
et al. [51]. Complete genomic plasmid HPV16 DNA
probe (cloned in pBR322 vector, kindly obtained by the
Karolinska Institute, International HPV Reference Center,
Forskningsgatan, Stockholm, Sveden) was biotin labeled
(Biotin NT Labelling Kit, Jena Bioscience, Borsea, Rovigo,
Italy) according to the manufacturer’s instructions. Depar-
affinized and rehydrated sections, after target denaturation
in 50 μg/ml proteinase K for 20 min at 37 °C and unmask-
ing in EDTA 1 mM pH 8 for 50 min at 95 °C, were heated
for 5 min at 95 °C with the BIO-labeled HPV16 DNA
probe and incubated overnight (ON) at 37 °C.
After stringent washes, sections were blocked for 1 h at
room temperature (RT) with 1% bovine serum albumin
(BSA) plus 0.2% gelatin from cold water fish skin in PBS
1x (all from Sigma). BIO-labeled DNA was revealed by
using an ABC kit (Vector Laboratories, distributed by
DBA Italia Srl, Segrate, Italy) followed by a Tyramide
Signal Amplification kit (TSA, Perkin Elmer, distributed
by Thermo Scientific, Milan, Italy), according to the man-
ufacturer’s instructions. HPV DNA positive cells were evi-
denced in red, while cell nuclei were counterstained in
blue with DAPI (Fig. 2A-B).
For BrdU epitope retrieval, a 2 N HCl treatment,
followed by a 1:200 diluted primary mouse monoclonal
anti-BrdU antibody (BU-33, Sigma Aldrich) incubation
(both for 1 h at 37 °C) was performed. BrdU was de-
tected with an Alexa Fluor 488 dye conjugated specific
secondary antibody (Fig. 2C-D).
Viral proteins expression
To assess HPV16 oncoproteins expression inside the 3D
in vitro epithelium, a direct immunofluorescent and a
western blot analysis were performed. Uninfected normal
and E6E7 HPV16 positive 3D cultures were ON incubated
at 4 °C with the following monoclonal mouse primary
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antibodies: anti HPV16/18 E6 (clone C1P5, working dilu-
tion 1:100, Santa Cruz Biotechnology, distributed by DBA
Italia, Segrate, Milan, Italy) and anti HPV16 E7 (clone
ED17, working dilution 1:50, Santa Cruz Biotechnology).
For antigens retrieval, all sections were incubated in
1 mM EDTA pH 8 for 50 min at 95 °C. Both E6 and E7 in-
cubations were followed by the addition of the MACH3
mouse HRP-polymer (BIOCARE Medical, distributed by
Space Import Export, Milan, Italy), according to the
manufacturer’s instructions, and TSA signal development
(Fig. 2E-F-F’-G-H-H′).
Protein extracts were obtained by peeling off the epi-
thelial layers of the reconstructed epithelium from the
collagen based dermis, then cut into small pieces with a
surgeon knife, subjected to 3 sonication cycles and fi-
nally lysed in RIPA buffer (0.1 M Tris-HCl pH 7.4,
0.3 M NaCl, 2% Triton X100, 2% Sodium dehoxycholate
and 0.2% SDS) plus inhibitors (1 mM PMSF, 0.5 mM
Sodium pirofosphate, 50 mM Sodium fluoride, 0.2 mM
Sodium orthovanadate, protease inhibitor cocktail and
50 U/μl Benzonase).
Sixty μg of protein extracts were run onto 10% and/or
15% SDS-polyacrilamide gels and then transferred onto
nitrocellulose (GE Healthcare, Milan, Italy) and/or PVDF
membranes (EMD Millipore Corporation, Milan, Italy).
Membranes were probed with the following primary
antibodies: anti-E6 (working dilution 1:500) and anti-E7
(working dilution 1:300). A mouse anti-tubulin antibody
(working dilution 1:2000, clone DM1A, abcam) was used
as internal protein loading normalization control (Fig. 2I).
A peroxidase goat anti-mouse antibody (working dilu-
tion 1:2000, abcam) incubation was followed by anti-
gens detection using an enhanced chemiluminescence kit
(SuperSignal West Pico Chemiluminescent Substrate,
Thermo Fisher Scientific, Rockford, IL, USA). Images
were acquired by the Quantity One software (version
4.6.9; Bio-Rad Laboratories, Segrate, Milan, Italy).
Characterization of the DDR in the 3D in vitro HPV16
epithelial models
DSBs sensors protein-protein detection
Uninfected normal and E6E7 HPV16 positive 3D cultures
were processed by both IF and biochemical analysis.
In vitro cultures slides were ON incubated at 4 °C with
the following primary antibodies: mouse anti-γH2A.X
(clone JBW301, working dilution 1:400, EMD Millipore
Corp., USA, distributed by Merck, Darmstadt, Germany)
and rabbit polyclonal anti-53BP1 (ab36823, working
dilution 1:1000, abcam).
For antigens retrieval, all sections were incubated in
1 mM EDTA pH 8 for 50 min at 95 °C. γH2A.X and
53BP1 incubations were respectively followed by the
addition of Alexa Fluor 568 and 488 dyes conjugated
specific secondary antibodies, according to the manu-
facturer’s instructions, and TSA signal development
(Fig. 3A-C, C’, C″).
Fig. 1 H&E staining. A) Control in vitro reconstructed 3D epithelial culture made up with normal keratinocytes and B) E6E7 HPV16 transduced
keratinocytes. C) In vivo normal epithelia obtained from tumor-free mucosa margins. D) HPV16 positive anal intraepithelial neoplasia (AIN), grade
III. Bar scales in 20x fields = 100 μm
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Protein extracts were then obtained, run, transferred and
detected as above described. Membranes were probed with
the following primary antibodies: anti-γH2A.X (working
dilution 1:1000), anti-53BP1 (working dilution 1:1000)
and anti-tubulin as internal control (Fig. 3B). A
peroxidase-coupled goat anti-rabbit (working dilution
1:2000, abcam) or anti-mouse antibody (working
dilution 1:2000, abcam) incubation was made. Anti-
gens were then revealed as above described.
E6-E7/cyclin E2-cyclin B1 and E6-E7/53BP1 protein-protein
detection
A double co-staining of E6 and E7 with cyclin E2 and
B1 respectively (Fig. 4B-C for E6 and F-G for E7) was
Fig. 2 In vitro 3D epithelial cultures. HPV16 DNA (FISH) staining and immunofluorescent detection of BrdU, E6 and E7 of control normal and E6E7
HPV16 infected reconstructed in vitro 3D epithelial cultures. Viral genome amplification positivity is evidenced in red in the mid and upper strata
of the infected epithelium only (A, B). To show cell nuclei, sections are counterstained with DAPI (blue). S phase cells positivity to the BrdU
marker is limited to the basal and basal/parabasal strata of normal (C) and infected epithelia (D) respectively. Direct analysis of E6 and E7 proteins
in normal uninfected (E and G for E6 and E7 respectively) and E6E7 HPV16 positive culture sections (F-F′ for E6 and H-H′ for E7). Positive cells are
shown in red, while cells nuclei are counterstained in blue with DAPI. Bar scales in 20x fields = 100 μm. Immunoblotting. Western blot analysis of
E6, E7 and tubulin protein extracts derived by peeling off the epithelial layers of 3D reconstructed epithelial cultures (control normal and
E6E7HPV16) from the collagen-based dermis. After run on polyacrylamide gels, proteins were blotted onto nitrocellulose or PVDF membranes (I)
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performed onto 3D epithelia. Antigens were respectively
detected, after a 1 mM EDTA pH 8 unmasking for
50 min at 95 °C, by applying the anti-HPV16/18 E6 or
anti HPV16 E7 with anti-Cyclin-E2 (Clone EP454Y;
working dilution 1:250, abcam, distributed by Thermo
Scientific, Milan, Italy) and Cyclin-B1 (Clone EPR17060;
working dilution 1:250, abcam) monoclonal antibodies
for 4 h at RT followed by an incubation with the respect-
ive Alexa Fluor-conjugated secondary antibodies (1:200,
Molecular Probes, Oregon, USA) for 1 h at RT.
A double staining for E6 and E7 with 53BP1 (working
dilution 1:200) was then setup (Fig. 4A-A’-A”-D for E6/
53BP1 and Fig. 4E-E’-E”-H for E7/53BP1) onto CaSki
cells and 3D culture sections.
To perform the proteins co-detection onto CaSki cells,
they were grown until 95% confluence, detached by trypsin
and centrifuged for 5 min at 900 rpm. Pellets were washed
twice in PBS 1X, centrifuged for 10 min at 1200 rpm and
resuspended in 100 μl of pre-warmed (50 °C) 2% agar solu-
tion and let solidify for 20 min at RT.
All immunostained sections were counterstained in
blue with DAPI and mounted for image acquisition with
a DM6000B inverted fluorescence microscope equipped
with DFC350FX digital camera (Leica Microsystems,
Milan, Italy).
Sequence analysis
Aminoacid sequence of 53BP1 protein was acquired from
the GenBank database, National Center for Biotechnology
Information, https://www.ncbi.nlm.nih.gov/protein/12392
90988. Sequence analysis of 53BP1 protein was made by
BLASTP 2.8.0+ software [22].
Immunofluorescent in situ proximity ligation assay (PLA)
Since PLA technology allows the in situ detection, with
sub-cellular resolution and molecular biology precision
(0–40 nm), of protein-protein interactions within tissues
[42, 43, 52–58], we revealed E6 and E7 antigens binding
with 53BP1 by circularized, ligated and amplified comple-
mentary and fluorescent labeled oligonucleotides bounded
antibodies in the 3D model. Two negative controls were
performed (data not shown) by: i) omission of the primary
antibodies and ii) single antibody incubation. CaSki cells,
used as positive control [59], were fixed, like E6E7HPV16
NHEKs, and paraffin-embedded as previously described.
Briefly, after EDTA unmasking, HPV16 positive 3D
culture sections were incubated with Duolink blocking
buffer (Duolink® In Situ Starter Kit Mouse/Rabbit, Sigma
Aldrich) for 30 min at 37 °C, then ON at 4 °C with the
specific primary antibodies (53BP1/E6 and 53BP1/E7)
combinations. Sections were secondarily incubated with
anti-rabbit PLUS and anti-mouse MINUS PLA probes
(working ratio 1:5) for 1 h at 37 °C. Ligation was per-
formed for 30 min at 37 °C and signals were amplified
with Duolink In Situ Detection Reagent Red for 100 min
at 37 °C and mounted with Duolink Mounting Medium
after DAPI counterstaining. Positive protein-protein inter-
action signals were displayed as red fluorescent spots.
Fig. 3 DDR characterization of the 3D in vitro reconstructed E6E7 HPV16 infected epithelia. Double immunofluorescent and western blot (B)
analysis of the DNA break sensors. γH2A.X (in red) and 53BP1 (in green) in control normal (A) and E6E7HPV16 infected epithelia (C-C′-C″). γH2A.X
and 53BP1 are expressed in HPV infected 3D samples
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Ethical approval
An approval for this study (prot. n. 620/CE, study n. CE
40/14), carried out in accordance with the declaration of
Helsinki as revised in 2013, was granted by the Hospital
Research Ethics Committee of Novara (Italy). Board
members: President - Roberto Fantozzi; Components -
Gian Carlo Avanzi, Maria Angela Brustia, Claudio De
Pieri, Roberto Fantozzi, Edoardo Ferlito, Lorenzo Giudice,
Gianenrico Guida, Corrado Magnani, Francesco Pia,
Alessia Pisterna, Pacifico Uglietti, Libero Zannino.
Results
The 3D in vitro epithelial cultures resembled the
histology of in vivo tissues
To assess the morphology of the 3D reconstructed epi-
thelia, a H/E staining was performed. The 3D normal
Fig. 4 Double immunofluorescent analysis of E6 and E7 with cyclin E2 and B1. E6 and E7 HPV16 pushes a subset of differentiating cells into G1/S
(cyclin E2 positive cells, B and F) and S/G2 checkpoint phases (cyclin B1 positive cells, C and G). Double immunofluorescent analysis of E6 and E7
with 53BP1. CaSki cells have a high number of discrete small 53BP1 positive nuclear foci inside most of the same cells that were E6 (A-A’-A”) and
E7 (E, E’, E”) positive; in HPV16 epithelial models E6/53BP1 (D) and E7/53BP1 (H) positivity is throughout the epithelium, both in undifferentiated
and differentiated layers. Nuclei were always visualized in blue with DAPI counterstaining. Bar scales in 20x fields = 100 μm
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and E6E7HPV16 epithelial models completely resemble
the typical histology of both in vivo normal and HPV16
infected AINIII epithelia (Fig. 1A-D).
Particularly, in vitro reconstructed and in vivo normal
squamous epithelia show the same thickness, organized
stratification and keratinization, while in vitro E6E7HPV16
and in vivo HPV16 positive ones are both thicker, with the
typical dysplastic multilayered pattern and superficial
hyperkeratosis.
3D in vitro epithelial cultures
HPV16 DNA expression is restricted to BrdU negative cells
To confirm the presence of HPV16 DNA in the 3D epi-
thelial sections, a FISH assay was performed. As shown in
Fig. 2B, the HPV16 DNA-FISH specific dot-like punctuate
nuclear pattern is clearly visible in the in vitro recon-
structed HPV positive 3D model. As in vivo occurs, the
staining is distributed inside the epithelium, evidencing
the characteristic viral genome amplification, promoted by
E6E7 oncoproteins, that occurs mainly in the middle and
more superficial layers. No signal is visible in the unin-
fected in vitro 3D control cultures (Fig. 2A).
The majority of cells showing intense red positive
staining for HPV16 DNA is negative for the BrdU signal,
indeed strongly present in S phase cells as depicted in
Fig. 2D. S phase BrdU positive cells are confined only in
the basal layer of the control cultures (Fig. 2C).
E6/E7 oncoproteins expression in HPV16 infected 3D
epithelia
A direct immunofluorescent analysis for the viral onco-
proteins presence was performed. Early E6E7HPV16
oncoproteins are distributed into the nuclei of basal and
differentiated epithelial cells as shown in red in Fig. 2F-F’
and H-H′ in the HPV16 infected epithelia, while they are
completely absent in normal 3D epithelia (Fig. 2E, G). E6
and E7 oncoproteins expression was confirmed by a west-
ern blot analysis (Fig. 2I).
Characterization of the DDR in the 3D in vitro HPV16
epithelial models
γH2A.X and 53BP1 DSBs sensors upregulation in HPV
infected 3D epithelia
HPV16 oncoproteins induce DNA damage response as
shown by the phosphorylation of the histone variant
H2A.X (γH2A.X), which is a sensor of DNA lesions, and
by the increase of the number of 53BP1-positive foci
with punctuate signals, respect to the normal epithelium
(Fig. 3A), in both undifferentiated and differentiated
layers (Fig. 3C-C’-C″). Noticeable γH2A.X-positive foci
are mainly evident in the mid-upper strata (Fig. 3C).
These data were confirmed by a western blot analysis
(Fig. 3B).
E6 and E7 tissue distribution partially overlaps with that of
cyclin E2, B1 and 53BP1
A double immunofluorescent analysis of E6 and E7,
together with cyclin E2 and B1 proteins, was made. As
noticeable, according to cell cycle analysis, it is possible
to observe that E6 and E7 HPV16 increase the prolifer-
ation by pushing differentiating cells into G1/S (cyclin
E2 positive cells; Fig. 4B for E6/cyclin E2 and 4F for E7/
cyclin E2) and S/G2 phases (cyclin B1 positive cells;
Fig. 4C for E6/cyclin B1 and 4G for E7/cyclin B1). To
gain evidence of the possible interaction of E6 and E7
with 53BP1, we firstly performed immunofluorescent
analysis to assess their reciprocal cellular and tissue dis-
tribution. CaSki cells show a high number of discrete
53BP1-positive foci inside many E6 and E7 positive
cells (Fig. 4A-A’-A” and 4E-E’-E” for E6 and E7 respect-
ively); the same signals are visible in HPV positive
models throughout the epithelium (Fig. 4D for E6/
53BP1 and 4H for E7/53BP1).
The 53BP1 BRCT2 domain contains a leucin rich LXXLL
sequence
Sequence analysis [22] evidenced that 53BP1 protein con-
tains a leucin rich LXXLL sequence (LKVLL) located within
its BRCT2 domain (1869PRENPFQNLKVLLVSDQQQN---),
hence reinforcing our interaction hypothesis.
HPV16 E6 and E7 oncoproteins interact with 53BP1
Upon DNA DSBs, 53BP1 is recruited to the damaged
chromosomes to activate the so-called DDR, which culmi-
nates with the activation of p53 and pRb. When HPV16
infection occurs, the activation is impaired, since E6
and E7 bind and independently degrade the two cellular
tumor suppressors [60]. Based on the evidences above
highlighted and on the presence of a LXXLL sequence
within 53BP1 BRCT2 domain and of E6 and E7 coloca-
lization with 53BP1 inside CaSki cells and in several
cells in the reconstructed epithelium, we hypothesized
that E6 and E7 oncoproteins could both interact with
53BP1.
To test this assumption, we investigated, and therefore
demonstrated by PLA technique, these bindings both in
CaSki and E6E7/HPV16NHEK cells and into the recon-
structed infected epithelium. The E6-53BP1 complexes
were mainly visible in the perinuclear compartment of
both the 2D and 3D models analyzed; the E7-53BP1
ones were also noticeable in the form of smallest punc-
tuate perinuclear signals; moreover in the 3D models,
dots were also present in the extracellular milieu, as
shown in Figs. 5A, B, C (for E6) and 5D, E, F (for E7). In
negative control sections, no signals were observed (data
not shown).
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Discussion
Cell replication fidelity is the result of the DDR, a
complex signaling proteins network that finds, re-
ports, and repairs lesions that occur to injured DNA.
Many DNA viruses actively promote their life cycles
through the inactivation of the host DDR, that or-
dinarily acts by blocking the cell cycle progression
[61]. On the contrary, despite the DDR turned on
that HR-HPVs have learned to drive, these viruses
highly promote the proliferation of the infected
squamous epithelial cells. Why and how HR-HPVs
activate the DDR through E6 and E7 oncoproteins,
thus favoring cancer progression, is still a matter of
debate; what it is known is that these events are not
so useful for maintaining, but rather for amplifying
viral DNA replication.
In particular, during HPV16 infection early phases, E6
oncoprotein manipulates the DDR response through the
link to p53 and degradation, mediated by LXXLL E6AP
binding motif; unfortunately, a direct role for E6 in the
DDR response has not clearly identified yet.
Similarly, E7 increases DDR proteins levels through sev-
eral main mechanisms: i) by competing with E2F1-pRb
interaction, thus leading to the inactivation of pRb, and to
the promotion, E2F1 mediated, of DDR genes translation,
ii) by binding to the pRb-like proteins CBP/p300 and
p107, that also harbour LXXLL sequence, and iii) via the
interaction and activation of several DDR proteins, most
of them yet unknown.
Therefore, it can be supposed that the DDR is
bypassed by the over-expression of the viral oncogenes
that promote cell cycle progression. Furthermore, several
recent studies sustain the hypothesis that HPV chroma-
tin its-self is modified by the DDR. In particular Gilles-
pie et al. demonstrated that γH2A.X, a marker for
cellular response to DNA damage, localizes to HPV rep-
lication compartments, inside nuclear foci, whose size
directly increases together with virus productive replica-
tion [12]. Importantly, γH2A.X was found to link to viral
DNA, suggesting the enrollment of cells repair factors
into specific viral replication sites. In support of this,
DDR components that rely on γH2A.X for recruitment
to DNA breaks, including 53BP1, Nbs1, BRCA1, and
Rad51, also localize to HPV replication compartments.
In particular E7 promotes DNA breaks accumulation in-
side cells harboring γH2A.X nuclear foci, while, even if
E6 can also increase DNA breaks, it seems not to pro-
mote γH2AX foci number [14]. To support these evi-
dences, Park et al. [62–64] demonstrated, in genetically
engineered murine models expressing E6 and E7 HPV16
oncoproteins, that HPV16 E7, alone or together with E6,
was able to promote an accumulation of γH2A.X nuclear
foci inside epithelial cells, while E6 alone did not.
In order to add evidences regarding E6 and E7 role in
the DDR, we firstly produced an in vitro 3D epithelium,
made of HPV16 E6E7 transduced keratinocytes, already
consolidated study model for HPVs, and assessed a H&E,
BrdU, HPV16 DNA and E6E7 proteins staining.
Fig. 5 E6 and E7 HPV16 oncoproteins interaction with 53BP1 proteins visualized with PLA technique. The red perinuclear punctuate dots visible
in the CaSki (A-D) and E6E7 HPV16 NHEKs (B-E) are also present in the HPV16 reconstructed infected epithelium (C and F). Nuclei were always
visualized in blue with DAPI counterstaining. Bar scales in 20x fields = 100 μm
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It is well known that γH2AX is the most suitable DNA
damage and repair sensor marker and that 53BP1 pro-
tein is one of the DDR components recruited to DNA
breaks [65–67]. To ascertain the DDR in the 3D in vitro
HPV16 epithelial model, we evaluated both γH2A.X and
53BP1 positive nuclear punctuate signals; they were both
present, but not in the normal counterpart, as expected.
Then we evaluated if also cyclins expression was in
line with what happens in vivo during HR-HPV infec-
tion. As described by the literature, cyclin E is physiolo-
gically produced in late G1 until cells enter in S phase
and then decreases. Moreover, DNA damaged S cells
normally inhibit activation and nuclear import of cyclin
B1-Cdk, master regulator of the entry in M phase, there-
fore stopping in G2 to avoid oncogenic transformation.
In DNA damaged HPV16 infected cells these cyclins are
no more modulated; indeed they are overexpressed, indi-
cating a clear propensity towards tumoral transform-
ation [68–70]. All these in vivo events, we observed
in vitro, are displayed in Fig. 4.
Several proteins, such as 53BP1, MDC1, BRCA1,
TOPBP1 and Claspin sense the DNA damage. Since
53BP1, like E6 and E7, is a binding partner of the central
DNA binding domain of p53, pRb, CBP/p300 and p107
pRb-like proteins, with whom it cooperates in tumor
suppression [35–37, 71–73], we hypothesized that E6
and E7 could bind to this DNA damage detector. In sup-
port to our hypothesis came the fact that defects in
DNA damage control checkpoints are able to promote
chromosome translocations and tumorigenesis, particu-
larly in the context in which p53 and pRb dependent
apoptosis is abrogated, like in case of E6 and E7 HPV16
overexpression [39].
To gain evidence on our hypothesis, we firstly per-
formed double immunofluorescent and biochemical
assays. Comforted by the evidence of the similar punctu-
ate localization pattern of 53BP1 and E6 and E7 proteins
in the 3D model (Fig. 4A, A’, A”, D, E, E’, E” and H), we
reinforced the association between HPV infection, DDR
and genome injury amplification also in CaSki and
E6E7HPV16 cells. CaSki, whose HPV16 genome is
known to be of about 600 copies of integrated DNA/cell,
highly express the E6E7 ORFs [59]. These cells, often
used to study chromosomal rearrangements and gen-
omic instability induced by HR-HPV infection and inte-
gration, were here utilized as control cells [10, 74].
Martinez-Zapien et al. [23] show that LXXLL motif con-
taining proteins could target E6 and E7; we therefore ana-
lyzed 53BP1 sequence and we found a LXXLL (LKVLL)
motif within its BRTC2 domain. By comparing this site
with those of p53 (LWKLL), we observed a similar total
charge. On the contrary, we detected the same total
charge among the E6AP- (LQELL), CBP/p300- (LQDLL)
and p107 (LDQLL) domains. This analysis let us suppose
that hydrophobicity and a slightly positivity of the leucin
rich motif could guarantee the optimal conformation to
allow the interaction with E6 and E7. Considering that E6
and E7 LXXLL motifs both contain hydrophilic, acid and
negative charged aminoacids, we supposed that 53BP1
pocket could enable not only E6- but also E7-53BP1
interactions.
Finally, we performed an in situ PLA technique, which
allowed us to detect the direct protein-protein E6-53BP1
and E7-53BP1 interactions within CaSki, E6E7HPV16
NHEKs cells and, more consistently, inside the in vitro re-
constructed infected tissue. The PLA signal is different be-
tween CaSki (2D) and 3D epithelial cultures; precisely, in
CaSki is cytoplasmic/perinuclear, while in 3D is mainly
nuclear.
Our data are in agreement with those of Dreier et al.; the
subcellular localization of endogenous HPV16 E7 oncopro-
tein varies during the cell cycle: many interphase (G1, S or
G2 phases) CaSki cells showed a predominantly diffuse
subcellular cytoplasmic HPV16 E7 expression with a ring
structure surrounding the nucleus (that occurs shortly in
the early G1 phase), while only few mitotic cells displayed a
faint nuclear pattern. It is likely that the nuclear E7 struc-
tures reflect well established nuclear E7 functions, such as
deregulation of the p16Ink4A/pRb pathway.
In the 3D model, E7 is mainly intranuclear where it
co-localize with 53BP1 that is present in mitotic cells
during telophase and cytokinesis [75].
The E6-53BP1 signal was mainly in the perinuclear
compartment in big complexes just where E6 is neces-
sary to degrade p53 [76], while the smallest E7-53BP1
perinuclear punctuate signals are also present in the
extracellular milieu of the 3D model, sign of E7 release
into the extracellular compartment where it is needed
to exert its immunosuppressive role in the in vivo con-
text [77].
These findings were reached thanks to the excellent PLA
technology, with its high sensibility and specificity that al-
lows to detect, as distinct spots, and with sub-cellular reso-
lution and molecular precision (0–40 nm), single-molecule
protein-protein interaction events. The exponential rolling
circle amplification that occurs produces very strong and
visible signals, also in case of limited number of interacting
molecules. This assay can in situ identify, validate and
characterize interactions in native proteins in their correct
tissue/cell context under near natural/physiological condi-
tions, without requiring protein content extraction from
tissue or the need to over-express the target proteins. Con-
versely, as also observed by other authors, since co-IP needs
high concentrations of both target proteins to generate ef-
fective signals and is often dependent on antibodies affinity
[42, 43, 52–58], it can’t be the right way to see protein in-
teractions in our 3D models where cellular density and
consequently target proteins are not so highly expressed.
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In situ PLA has 5-times higher specificity and sensibility
than IF [78], that conversely allows the detection of single
signals if only at a distance of approximately 0.2 μm.
In conclusion this study highlight, for the first time in
our knowledge, the interaction between HPV16 E6 and
E7 with the 53BP1 protein that is recruited inside nu-
clear foci after DNA damage. Further investigations on
mutants of the LVKLL motif are necessary to definitively
assess if the bindings occur just through this site.
The discovery of such interactions is important not only
to better understand proteins function and behavior, spe-
cifically of E6 and E7, but also to predict the biological
processes and pathways in which those proteins are in-
volved in. In our opinion these interactions could explain
why during HPV induced carcinogenesis 53BP1 doesn’t
correctly process the DDR signal and doesn’t define DSB
repair pathway choice in the G1 and S/G2 phases.
Conclusions
In short, we employed a highly sensible and specific
PLA assay for E6- and E7-53BP1 interactions detection;
our results reinforce once more HPV16 role in cellular
function control providing potentially new insights into
the activity of this tumor virus.
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